Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - 2026 is anticipated to be a significant year for Genmab, particularly regarding its late-stage pipeline [1] - The focus will be on three brands: EPKINLY, Rina-S, and petosemtamab, all of which have received FDA breakthrough therapy designation [1] Company Pipeline - Each of the three brands is expected to provide meaningful data in 2025, which is crucial for investor attention [1] - The FDA breakthrough therapy designation for all three brands highlights their potential in the market [1]